CLINICAL_TRIALS
trial_result
· 2025-10-28
Clinical Trial Update: A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia [Phase 2]
Summary
AbbVie completed a Phase 2 trial evaluating 15 mg and 30 mg doses of emraclidine (CVL-231) in schizophrenia, with the results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AbbVie | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2025-10-28